Marinus Pharmaceuticals Inc (NASDAQ:MRNS) CFO Edward F. Smith sold 24,211 shares of Marinus Pharmaceuticals stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $5.03, for a total value of $121,781.33. Following the completion of the sale, the chief financial officer now directly owns 20,097 shares in the company, valued at approximately $101,087.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of MRNS stock traded up $0.07 on Friday, hitting $4.29. The company had a trading volume of 332,606 shares, compared to its average volume of 661,593. The stock has a market cap of $221.54 million, a price-to-earnings ratio of -4.77 and a beta of 3.17. Marinus Pharmaceuticals Inc has a twelve month low of $2.36 and a twelve month high of $10.54.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). As a group, equities analysts forecast that Marinus Pharmaceuticals Inc will post -0.86 earnings per share for the current year.
Several research firms have weighed in on MRNS. Zacks Investment Research lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $24.50 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, May 1st. Mizuho downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $13.00 to $5.00 in a research note on Wednesday, February 27th. Cantor Fitzgerald restated a “buy” rating and issued a $22.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, May 1st. Finally, ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $14.93.
Several institutional investors and hedge funds have recently modified their holdings of MRNS. Jennison Associates LLC increased its position in Marinus Pharmaceuticals by 139.4% in the fourth quarter. Jennison Associates LLC now owns 4,554,759 shares of the biopharmaceutical company’s stock worth $13,072,000 after buying an additional 2,652,236 shares during the last quarter. BlackRock Inc. increased its position in Marinus Pharmaceuticals by 31.2% in the first quarter. BlackRock Inc. now owns 3,197,928 shares of the biopharmaceutical company’s stock worth $13,368,000 after buying an additional 759,827 shares during the last quarter. Tekla Capital Management LLC increased its position in Marinus Pharmaceuticals by 124.8% in the fourth quarter. Tekla Capital Management LLC now owns 755,776 shares of the biopharmaceutical company’s stock worth $2,169,000 after buying an additional 419,548 shares during the last quarter. Fosun International Ltd boosted its stake in Marinus Pharmaceuticals by 227.4% during the fourth quarter. Fosun International Ltd now owns 491,997 shares of the biopharmaceutical company’s stock valued at $1,378,000 after buying an additional 341,703 shares during the period. Finally, Highbridge Capital Management LLC bought a new stake in Marinus Pharmaceuticals during the fourth quarter valued at $762,000. 63.35% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Edward F. Smith Sells 24,211 Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Stock” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://sundanceherald.com/2019/06/14/insider-selling-marinus-pharmaceuticals-inc-mrns-cfo-sells-121781-33-in-stock.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More: Systematic Risk
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.